Joy Yang Ge
Kelun Group (China)(CN)Peking University Shenzhen Hospital(CN)University of Hong Kong(HK)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, CAR-T cell therapy research
Most-Cited Works
- → A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine(2016)245 cited
- → Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.(2016)85 cited
- → Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.(2015)68 cited
- → Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412(2020)58 cited
- → KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.(2019)51 cited
- → Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.